YYZ is taking a closer look at life… to uncover: New drug targets... New drug candidates... New diagnostics... Powered by: ELiMSA™ for Measurement – The most sensitive measurement available for life sciences. DPiPSA™ for Discovery – The most rigorous bioinformatics for proteomics, biomarker & target discovery. --- YYZ invents and develops diagnostic and therapeutic technology for use in modern pharmaceuticals, with breakthroughs in the discovery and ultra-sensitive quantification of biomolecules. YYZ is the commercialization partner of the Marshall Team at Toronto Metropolitan University (formerly Ryerson University). Technology Platform Highlights: ELiMSA™ (Enzyme Linked Mass Spectrometric Assay) – a patented detection method with industry-leading sensitivity, quantification and reliability in identifying biomolecules, using a combination of enzyme amplification with detection by mass spectrometry. DPiPSA™ (Database-Driven Proteome Intact Partition Statistical Analysis) – a biomarker discovery platform which generates large scale blood peptide and protein databases, using a combination of sample preparation techniques, mass spectrometry and a proprietary data analytic computation system.